{"id":"ags-experimental","safety":{"commonSideEffects":[{"rate":"null","effect":"Pneumonitis"},{"rate":"null","effect":"Hypothyroidism"},{"rate":"null","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"AGS works by binding to the PD-1 receptor on T cells, preventing its interaction with PD-L1 and thereby enhancing the immune response against cancer cells.","oneSentence":"AGS is an experimental drug that targets the PD-1/PD-L1 pathway.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:37.249Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT04963153","phase":"PHASE1","title":"Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-07","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma","enrollment":24},{"nctId":"NCT05488067","phase":"PHASE4","title":"Atorvastatin Therapy on Xanthoma in Alagille Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2022-03-22","conditions":"Alagille Syndrome, Atorvastatin, Xanthoma","enrollment":15},{"nctId":"NCT06311214","phase":"PHASE2","title":"Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-03-18","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm","enrollment":500},{"nctId":"NCT07232602","phase":"PHASE1, PHASE2","title":"KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-02-09","conditions":"Bladder Cancer","enrollment":55},{"nctId":"NCT05035030","phase":"PHASE3","title":"Long-term Safety and Efficacy of Odevixibat in Patients With Alagille Syndrome","status":"RECRUITING","sponsor":"Albireo, an Ipsen Company","startDate":"2021-09-03","conditions":"Alagille Syndrome","enrollment":70},{"nctId":"NCT06764095","phase":"PHASE4","title":"Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-01-08","conditions":"Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis and Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma","enrollment":75},{"nctId":"NCT05775471","phase":"PHASE2","title":"Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer","status":"RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2024-06-26","conditions":"Renal Pelvis and Ureter Urothelial Carcinoma","enrollment":21},{"nctId":"NCT05543174","phase":"PHASE3","title":"A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS)","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-01-16","conditions":"Alagille Syndrome (ALGS)","enrollment":7},{"nctId":"NCT04878029","phase":"PHASE1","title":"Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-07-23","conditions":"Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma","enrollment":32},{"nctId":"NCT07335523","phase":"PHASE2","title":"Management of Steatorrhea in Children and Young Adults With Alagille Syndrome After Liver Transplantation","status":"NOT_YET_RECRUITING","sponsor":"Digestive Care, Inc.","startDate":"2026-03","conditions":"Steatorrhea","enrollment":30},{"nctId":"NCT04748380","phase":"NA","title":"Shared Decision-making and Colorectal Cancer Screening","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2023-01-18","conditions":"Colorectal Cancer","enrollment":60},{"nctId":"NCT03921554","phase":"PHASE2","title":"JAK Inhibitor Treatment in AGS","status":"COMPLETED","sponsor":"Adeline Vanderver, MD","startDate":"2019-06-03","conditions":"Aicardi Goutieres Syndrome","enrollment":54},{"nctId":"NCT07290257","phase":"PHASE4","title":"Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)","status":"RECRUITING","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2025-09-25","conditions":"Alagille Syndrome","enrollment":100},{"nctId":"NCT06104618","phase":"PHASE2","title":"Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-12-21","conditions":"Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8","enrollment":28},{"nctId":"NCT07087860","phase":"PHASE2","title":"Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-01","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis and Ureter Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":70},{"nctId":"NCT02363452","phase":"PHASE2","title":"Reverse Transcriptase Inhibitors in AGS","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-09-10","conditions":"Aicardi-Goutières Syndrome (AGS)","enrollment":11},{"nctId":"NCT05756569","phase":"PHASE2","title":"Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-09-26","conditions":"Bladder Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Malignant Renal Pelvis Neoplasm","enrollment":25},{"nctId":"NCT04517253","phase":"PHASE2, PHASE3","title":"A Study of Baricitinib (LY3009104) in Adult and Pediatric Japanese Participants With NNS/CANDLE, SAVI, and AGS","status":"TERMINATED","sponsor":"Eli Lilly and Company","startDate":"2020-10-27","conditions":"Nakajo-Nishimura Syndrome, Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature Syndrome, STING-Associated Vasculopathy With Onset in Infancy","enrollment":10},{"nctId":"NCT03304717","phase":"PHASE1, PHASE2","title":"Reverse Transcriptase Inhibitors in Aicardi Goutières Syndrome","status":"WITHDRAWN","sponsor":"Children's Hospital of Philadelphia","startDate":"2025-12","conditions":"Aicardi Goutières Syndrome","enrollment":""},{"nctId":"NCT05613868","phase":"PHASE2","title":"TPN-101 in Aicardi-Goutières Syndrome (AGS)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Transposon Therapeutics, Inc.","startDate":"2023-03-15","conditions":"Aicardi-Goutières Syndrome (AGS)","enrollment":16},{"nctId":"NCT04729751","phase":"PHASE2","title":"A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2021-09-09","conditions":"Progressive Familial Intrahepatic Cholestasis, Alagille Syndrome, Cholestatic Liver Disease","enrollment":27},{"nctId":"NCT06630312","phase":"EARLY_PHASE1","title":"Glycemic Response of Whole Beans and Bean Products","status":"COMPLETED","sponsor":"Iowa State University","startDate":"2023-03-28","conditions":"Healthy, Body Mass Index, Normal, Postprandial Hyperglycemia","enrollment":21},{"nctId":"NCT04878562","phase":"NA","title":"I-COPE Study: Opioid Use and Pain Management in Older Adults","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2021-06-03","conditions":"Chronic Pain, Opioids, Opioid-use Disorder","enrollment":20000},{"nctId":"NCT02918565","phase":"NA","title":"Mechanisms for Alcohol Treatment Change [MATCH] Study","status":"COMPLETED","sponsor":"University of Pittsburgh","startDate":"2016-12","conditions":"Alcohol Consumption","enrollment":1131},{"nctId":"NCT02198690","phase":"NA","title":"Trial of a Mammography Decision Aid for Women Aged 75 and Older","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2014-09","conditions":"Breast Cancer Screening","enrollment":541},{"nctId":"NCT04674761","phase":"PHASE3","title":"Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome","status":"COMPLETED","sponsor":"Albireo","startDate":"2021-03-19","conditions":"Alagille Syndrome","enrollment":52},{"nctId":"NCT05846854","phase":"NA","title":"Decreasing Hemorrhage Risk in Children With Alagille Syndrome","status":"UNKNOWN","sponsor":"Stanford University","startDate":"2023-04-18","conditions":"Alagille Syndrome, Pulmonary Artery Stenoses, Acquired Von Willebrand Disease","enrollment":40},{"nctId":"NCT04009824","phase":"PHASE1","title":"Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-07-08","conditions":"Mosquito-Borne Infectious Diseases","enrollment":51},{"nctId":"NCT05344638","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Safety and Efficacy of \"AG1904\" in Acute Bronchitis","status":"COMPLETED","sponsor":"Ahn-Gook Pharmaceuticals Co.,Ltd","startDate":"2019-10-17","conditions":"Acute Bronchitis","enrollment":220},{"nctId":"NCT02047318","phase":"PHASE2","title":"An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2013-12-20","conditions":"Alagille Syndrome","enrollment":19},{"nctId":"NCT02160782","phase":"PHASE2","title":"Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2014-10-28","conditions":"Alagille Syndrome","enrollment":31},{"nctId":"NCT02117713","phase":"PHASE2","title":"An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2015-03-16","conditions":"Alagille Syndrome","enrollment":34},{"nctId":"NCT03055000","phase":"PHASE1","title":"Safety and Immunogenicity of a First-in-Human Mosquito Saliva Peptide Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2017-02-15","conditions":"Mosquito-Borne Disease","enrollment":49},{"nctId":"NCT01903460","phase":"PHASE2","title":"Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2013-08","conditions":"Alagille Syndrome","enrollment":20},{"nctId":"NCT02057692","phase":"PHASE2","title":"Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome","status":"COMPLETED","sponsor":"Mirum Pharmaceuticals, Inc.","startDate":"2014-11-24","conditions":"Alagille Syndrome","enrollment":37},{"nctId":"NCT02026960","phase":"NA","title":"RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)","status":"TERMINATED","sponsor":"Duke University","startDate":"2014-03","conditions":"Metastatic Renal Cell Carcinoma, Genitourinary Cancer (Bladder, Prostate or Testicular)","enrollment":14},{"nctId":"NCT02042248","phase":"PHASE1","title":"A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004","status":"COMPLETED","sponsor":"Cynthia L Gay, MD","startDate":"2014-03","conditions":"HIV","enrollment":6},{"nctId":"NCT00664482","phase":"NA","title":"A Single-Patient Study Using AGS 006","status":"COMPLETED","sponsor":"Argos Therapeutics","startDate":"2007-05","conditions":"Pancreatic Cancer","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":720,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"AGS (Experimental)","genericName":"AGS (Experimental)","companyName":"Ahn-Gook Pharmaceuticals Co.,Ltd","companyId":"ahn-gook-pharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGS is an experimental drug that targets the PD-1/PD-L1 pathway. Used for Metastatic non-small cell lung cancer, PD-L1 positive, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}